{"id":2425,"date":"2017-11-15T15:01:53","date_gmt":"2017-11-15T13:01:53","guid":{"rendered":"https:\/\/colox.ch\/?p=2425"},"modified":"2018-03-09T12:17:39","modified_gmt":"2018-03-09T11:17:39","slug":"cancer-du-colon-une-innovation-made-in-switzerland","status":"publish","type":"post","link":"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/","title":{"rendered":"Colox : une innovation \u00abmade in Switzerland\u00bb"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"--awb-bg-size:cover;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-text fusion-text-1\"><h3>Le cancer du c\u00f4lon tue 5 personnes par jour en Suisse. \u00ab Une r\u00e9alit\u00e9 inadmissible \u00bb s\u2019insurge Brian Haschemi, chairman de Novigenix, start-up biotech situ\u00e9e au coeur du Biop\u00f4le \u00e0 Lausanne. Inadmissible car une d\u00e9tection pr\u00e9coce du cancer colorectal permet sa gu\u00e9rison. Aujourd\u2019hui 2e cancer le plus meurtrier, l\u2019\u00e9radication du cancer colorectal repr\u00e9sente \u00e0 la fois un d\u00e9fi de sant\u00e9 mondiale et un march\u00e9 \u00e0 fort potentiel.<\/h3>\n<p>Soci\u00e9t\u00e9 suisse innovante sp\u00e9cialis\u00e9e dans les techniques mol\u00e9culaires, Novigenix d\u00e9veloppe une nouvelle g\u00e9n\u00e9ration de tests sanguins. Son produit-phare, <a href=\"https:\/\/colox.ch\/cancer-du-colon\/\">Colox\u00ae<\/a>, r\u00e9pond \u00e0 un besoin clinique fort : la disponibilit\u00e9 sur le march\u00e9, en routine m\u00e9dicale, d\u2019un produit simple de pr\u00e9vention et de d\u00e9tection pr\u00e9coce du cancer colorectal. Le cancer du c\u00f4lon est le deuxi\u00e8me cancer le plus meurtrier au monde et le troisi\u00e8me plus fr\u00e9quent : une personne sur 20 en d\u00e9veloppera un au cours de sa vie. En Suisse, 5 individus \u2013 hommes et femmes &#8211; en meurent chaque jour et 4 800 nouveaux cas sont recens\u00e9s chaque ann\u00e9e. Fruit de 10 ans de d\u00e9veloppement avec des acteurs-cl\u00e9s (ISREC, Universit\u00e9 de Lausanne, SIB, EPFL, CHUV, H\u00f4pital Universitaire de B\u00e2le), Colox\u00ae combine diff\u00e9rentes technologies de biologie mol\u00e9culaire et de biostatistique.<\/p>\n<p>L\u2019innovation intrins\u00e8que du<a href=\"https:\/\/colox.ch\/colox\/\"> test sanguin de nouvelle g\u00e9n\u00e9ration Colox\u00ae<\/a> r\u00e9side dans l\u2019interrogation du syst\u00e8me immunitaire du patient. Il permet ainsi une d\u00e9tection pr\u00e9coce d\u2019une tumeur canc\u00e9reuse ou pr\u00e9canc\u00e9reuse (polypes pouvant \u00eatre retir\u00e9s par endoscopie), ce qui augmente radicalement les chances de survie. Le taux de survie \u00e0 5 ans est de 90 % si la d\u00e9tection est pr\u00e9coce mais tombe \u00e0 10 % seulement si le cancer colorectal est diagnostiqu\u00e9 \u00e0 un stade avanc\u00e9. <a href=\"https:\/\/colox.ch\/colox\/\">Colox\u00ae<\/a> est une alternative aux m\u00e9thodes de diagnostic habituelles (coloscopie ou tests des selles). Simple, propre, fiable, <a href=\"https:\/\/colox.ch\/cancer-du-colon\/\">Colox\u00ae<\/a> contribue \u00e0 r\u00e9duire les barri\u00e8res d\u2019acc\u00e8s au d\u00e9pistage. En cas de test positif, le m\u00e9decin prescrira la coloscopie. Effectu\u00e9 tous les deux ans \u00e0 partir de 50 ans, un test de d\u00e9pistage permet de pr\u00e9venir la progression de ce cancer.<\/p>\n<p>\u00c0 l\u2019heure actuelle, 400 m\u00e9decins ont d\u00e9j\u00e0 prescrit <a href=\"https:\/\/colox.ch\/colox\/\">Colox\u00ae<\/a> \u00e0 plus de 3 000 patients. Ce n\u2019est qu\u2019un d\u00e9but : Novigenix entend bien accro\u00eetre la disponibilit\u00e9 du test au plus grand bassin possible de population en concluant de nouveaux accords de distribution avec des laboratoires d\u2019analyses en Suisse romande et al\u00e9manique. Novigenix a publi\u00e9 en 2016 une \u00e9tude de validation clinique de <a href=\"https:\/\/colox.ch\/colox\/\">Colox\u00ae<\/a> dans la prestigieuse revue Clinical Cancer Research. Depuis, l\u2019entreprise multiplie les \u00e9v\u00e9nements \u00e0 l\u2019attention des m\u00e9decins et se tient \u00e0 la disposition des patients pour r\u00e9pondre \u00e0 leurs questions. En parall\u00e8le, Novigenix continue \u00e0 se baser sur son r\u00e9seau d\u2019experts en Suisse pour d\u00e9velopper de nouveaux produits diagnostics pour le suivi clinique des patients atteints du cancer colorectal et de maladies inflammatoires chroniques de l\u2019intestin, avec une volont\u00e9 affich\u00e9e de se d\u00e9velopper \u00e0 l\u2019\u00e9chelle internationale.<\/p>\n<\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":2427,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[42],"class_list":["post-2425","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-cancer-du-colon"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Colox : une innovation \u00abmade in Switzerland\u00bb - Colox<\/title>\n<meta name=\"description\" content=\"Le cancer du c\u00f4lon tue 5 personnes par jour en Suisse. \u00ab Une r\u00e9alit\u00e9 inadmissible \u00bb s\u2019insurge Brian Haschemi, chairman de Novigenix, start-up biotech situ\u00e9e au coeur du Biop\u00f4le \u00e0 Lausanne. Inadmissible car une d\u00e9tection pr\u00e9coce du cancer colorectal permet sa gu\u00e9rison.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Colox : une innovation \u00abmade in Switzerland\u00bb - Colox\" \/>\n<meta property=\"og:description\" content=\"Le cancer du c\u00f4lon tue 5 personnes par jour en Suisse. \u00ab Une r\u00e9alit\u00e9 inadmissible \u00bb s\u2019insurge Brian Haschemi, chairman de Novigenix, start-up biotech situ\u00e9e au coeur du Biop\u00f4le \u00e0 Lausanne. Inadmissible car une d\u00e9tection pr\u00e9coce du cancer colorectal permet sa gu\u00e9rison.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/\" \/>\n<meta property=\"og:site_name\" content=\"Colox\" \/>\n<meta property=\"article:published_time\" content=\"2017-11-15T13:01:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-03-09T11:17:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/colox.ch\/wp-content\/uploads\/2017\/11\/novigenix-illustrations-cancer-colon-760px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"760\" \/>\n\t<meta property=\"og:image:height\" content=\"578\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nicolas Demierre\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Demierre\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/\"},\"author\":{\"name\":\"Nicolas Demierre\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/person\/6c3d7bdab24ae49fe6aa2dbfb4789232\"},\"headline\":\"Colox : une innovation \u00abmade in Switzerland\u00bb\",\"datePublished\":\"2017-11-15T13:01:53+00:00\",\"dateModified\":\"2018-03-09T11:17:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/\"},\"wordCount\":678,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/colox.ch\/de\/#organization\"},\"image\":{\"@id\":\"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/colox.ch\/wp-content\/uploads\/2017\/11\/novigenix-illustrations-cancer-colon-760px.jpg\",\"keywords\":[\"Cancer du c\u00f4lon\"],\"articleSection\":[\"News Novigenix\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/\",\"url\":\"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/\",\"name\":\"Colox : une innovation \u00abmade in Switzerland\u00bb - Colox\",\"isPartOf\":{\"@id\":\"https:\/\/colox.ch\/de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/colox.ch\/wp-content\/uploads\/2017\/11\/novigenix-illustrations-cancer-colon-760px.jpg\",\"datePublished\":\"2017-11-15T13:01:53+00:00\",\"dateModified\":\"2018-03-09T11:17:39+00:00\",\"description\":\"Le cancer du c\u00f4lon tue 5 personnes par jour en Suisse. \u00ab Une r\u00e9alit\u00e9 inadmissible \u00bb s\u2019insurge Brian Haschemi, chairman de Novigenix, start-up biotech situ\u00e9e au coeur du Biop\u00f4le \u00e0 Lausanne. Inadmissible car une d\u00e9tection pr\u00e9coce du cancer colorectal permet sa gu\u00e9rison.\",\"breadcrumb\":{\"@id\":\"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/#primaryimage\",\"url\":\"https:\/\/colox.ch\/wp-content\/uploads\/2017\/11\/novigenix-illustrations-cancer-colon-760px.jpg\",\"contentUrl\":\"https:\/\/colox.ch\/wp-content\/uploads\/2017\/11\/novigenix-illustrations-cancer-colon-760px.jpg\",\"width\":760,\"height\":578,\"caption\":\"colorectal cancer innovation switzerland\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/colox.ch\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Colox : une innovation \u00abmade in Switzerland\u00bb\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/colox.ch\/de\/#website\",\"url\":\"https:\/\/colox.ch\/de\/\",\"name\":\"Colox\",\"description\":\"The new generation blood test\",\"publisher\":{\"@id\":\"https:\/\/colox.ch\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/colox.ch\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/colox.ch\/de\/#organization\",\"name\":\"Novigenix SA\",\"url\":\"https:\/\/colox.ch\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png\",\"contentUrl\":\"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png\",\"width\":700,\"height\":297,\"caption\":\"Novigenix SA\"},\"image\":{\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/person\/6c3d7bdab24ae49fe6aa2dbfb4789232\",\"name\":\"Nicolas Demierre\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/colox.ch\/wp-content\/uploads\/2017\/10\/Nicolas-Demmi\u00e8re_avatar-96x96.jpg\",\"contentUrl\":\"https:\/\/colox.ch\/wp-content\/uploads\/2017\/10\/Nicolas-Demmi\u00e8re_avatar-96x96.jpg\",\"caption\":\"Nicolas Demierre\"},\"description\":\"Dr. Nicolas Demierre is the Chief Operating Officer focusing on operations, business development, and engagement of strategic partners. Nicolas holds a PhD in Applied Sciences and an Executive MBA degree from HEC. Prior to joining Novigenix Nicolas was head of sales and business development at Mycartis, a spinoff of Biocartis.\",\"sameAs\":[\"https:\/\/colox.ch\"],\"url\":\"https:\/\/colox.ch\/fr\/author\/nicolas\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Colox : une innovation \u00abmade in Switzerland\u00bb - Colox","description":"Le cancer du c\u00f4lon tue 5 personnes par jour en Suisse. \u00ab Une r\u00e9alit\u00e9 inadmissible \u00bb s\u2019insurge Brian Haschemi, chairman de Novigenix, start-up biotech situ\u00e9e au coeur du Biop\u00f4le \u00e0 Lausanne. Inadmissible car une d\u00e9tection pr\u00e9coce du cancer colorectal permet sa gu\u00e9rison.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/","og_locale":"fr_FR","og_type":"article","og_title":"Colox : une innovation \u00abmade in Switzerland\u00bb - Colox","og_description":"Le cancer du c\u00f4lon tue 5 personnes par jour en Suisse. \u00ab Une r\u00e9alit\u00e9 inadmissible \u00bb s\u2019insurge Brian Haschemi, chairman de Novigenix, start-up biotech situ\u00e9e au coeur du Biop\u00f4le \u00e0 Lausanne. Inadmissible car une d\u00e9tection pr\u00e9coce du cancer colorectal permet sa gu\u00e9rison.","og_url":"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/","og_site_name":"Colox","article_published_time":"2017-11-15T13:01:53+00:00","article_modified_time":"2018-03-09T11:17:39+00:00","og_image":[{"width":760,"height":578,"url":"https:\/\/colox.ch\/wp-content\/uploads\/2017\/11\/novigenix-illustrations-cancer-colon-760px.jpg","type":"image\/jpeg"}],"author":"Nicolas Demierre","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Nicolas Demierre","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/#article","isPartOf":{"@id":"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/"},"author":{"name":"Nicolas Demierre","@id":"https:\/\/colox.ch\/de\/#\/schema\/person\/6c3d7bdab24ae49fe6aa2dbfb4789232"},"headline":"Colox : une innovation \u00abmade in Switzerland\u00bb","datePublished":"2017-11-15T13:01:53+00:00","dateModified":"2018-03-09T11:17:39+00:00","mainEntityOfPage":{"@id":"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/"},"wordCount":678,"commentCount":0,"publisher":{"@id":"https:\/\/colox.ch\/de\/#organization"},"image":{"@id":"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/#primaryimage"},"thumbnailUrl":"https:\/\/colox.ch\/wp-content\/uploads\/2017\/11\/novigenix-illustrations-cancer-colon-760px.jpg","keywords":["Cancer du c\u00f4lon"],"articleSection":["News Novigenix"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/","url":"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/","name":"Colox : une innovation \u00abmade in Switzerland\u00bb - Colox","isPartOf":{"@id":"https:\/\/colox.ch\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/#primaryimage"},"image":{"@id":"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/#primaryimage"},"thumbnailUrl":"https:\/\/colox.ch\/wp-content\/uploads\/2017\/11\/novigenix-illustrations-cancer-colon-760px.jpg","datePublished":"2017-11-15T13:01:53+00:00","dateModified":"2018-03-09T11:17:39+00:00","description":"Le cancer du c\u00f4lon tue 5 personnes par jour en Suisse. \u00ab Une r\u00e9alit\u00e9 inadmissible \u00bb s\u2019insurge Brian Haschemi, chairman de Novigenix, start-up biotech situ\u00e9e au coeur du Biop\u00f4le \u00e0 Lausanne. Inadmissible car une d\u00e9tection pr\u00e9coce du cancer colorectal permet sa gu\u00e9rison.","breadcrumb":{"@id":"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/#primaryimage","url":"https:\/\/colox.ch\/wp-content\/uploads\/2017\/11\/novigenix-illustrations-cancer-colon-760px.jpg","contentUrl":"https:\/\/colox.ch\/wp-content\/uploads\/2017\/11\/novigenix-illustrations-cancer-colon-760px.jpg","width":760,"height":578,"caption":"colorectal cancer innovation switzerland"},{"@type":"BreadcrumbList","@id":"https:\/\/colox.ch\/fr\/cancer-du-colon-une-innovation-made-in-switzerland\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/colox.ch\/"},{"@type":"ListItem","position":2,"name":"Colox : une innovation \u00abmade in Switzerland\u00bb"}]},{"@type":"WebSite","@id":"https:\/\/colox.ch\/de\/#website","url":"https:\/\/colox.ch\/de\/","name":"Colox","description":"The new generation blood test","publisher":{"@id":"https:\/\/colox.ch\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/colox.ch\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/colox.ch\/de\/#organization","name":"Novigenix SA","url":"https:\/\/colox.ch\/de\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/","url":"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png","contentUrl":"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png","width":700,"height":297,"caption":"Novigenix SA"},"image":{"@id":"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/colox.ch\/de\/#\/schema\/person\/6c3d7bdab24ae49fe6aa2dbfb4789232","name":"Nicolas Demierre","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/colox.ch\/de\/#\/schema\/person\/image\/","url":"https:\/\/colox.ch\/wp-content\/uploads\/2017\/10\/Nicolas-Demmi\u00e8re_avatar-96x96.jpg","contentUrl":"https:\/\/colox.ch\/wp-content\/uploads\/2017\/10\/Nicolas-Demmi\u00e8re_avatar-96x96.jpg","caption":"Nicolas Demierre"},"description":"Dr. Nicolas Demierre is the Chief Operating Officer focusing on operations, business development, and engagement of strategic partners. Nicolas holds a PhD in Applied Sciences and an Executive MBA degree from HEC. Prior to joining Novigenix Nicolas was head of sales and business development at Mycartis, a spinoff of Biocartis.","sameAs":["https:\/\/colox.ch"],"url":"https:\/\/colox.ch\/fr\/author\/nicolas\/"}]}},"_links":{"self":[{"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/posts\/2425"}],"collection":[{"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/comments?post=2425"}],"version-history":[{"count":0,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/posts\/2425\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/media\/2427"}],"wp:attachment":[{"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/media?parent=2425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/categories?post=2425"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/tags?post=2425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}